Treats metastatic or locally advanced breast cancer resistant. Sold as Ixempra. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Ixabepilone (sold as Ixempra), first approved Oct 16, 2007, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| IXempra | Part B | $2.1M | -8% | 75 |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryAdult Solid Neoplasm · National Cancer Institute (NCI) | Phase 1 | Active, not recruiting | Jun 17, 2011 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Sep 15, 2009 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyBilateral Breast Carcinoma, HER2/Neu Negative · M.D. Anderson Cancer Center | Phase 2 | Active, not recruiting | Apr 7, 2009 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 16, 2007 | IxempraNDA 22065 · New molecular entity | R-Pharm US LLC | 11 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
